Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho
HIV Medicine · 2023-02 · 24 (2) · 153-162
DOI: 10.1111/hiv.13352 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift HIV Medicine, online erschienen am 22.06.2022. Verfasst von Jennifer A Brown und 10 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Tropical and Public Health Institute, Basel, Switzerland. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fondation Botnar.
Abstract (Originalsprache)
Introduction
HIV programmes across many countries in Africa have recently transitioned people living with HIV from efavirenz (EFV)‐ to dolutegravir (DTG)‐containing antiretroviral therapy (ART). As both drugs are associated with neuropsychiatric adverse effects, this study assessed the mental health and HIV/ART‐associated symptoms of people living with HIV before and after transition to DTG.
Methods
The prospective DO‐REAL cohort enrolled people starting DTG‐based ART in Lesotho from February to December 2020. For this analysis within DO‐REAL, we included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/EFV to TDF/3TC/DTG within first‐line therapy. At transition and 16 weeks thereafter, participants completed the Patient Health Questionnaire‐9 (PHQ‐9; depression screening), the 12‐item Short‐Form Health Survey (SF‐12; mental and physical health), and a modified HIV Symptom Index (mHSI; HIV/ART‐related symptoms). We also assessed weight change. We used McNemar tests with Bonferroni corrections to assess binary outcomes. ClinicalTrials.gov : NCT04238767.
Results
Among 1228 participants, 1131 completed follow‐up. Of these, 60.0% were female, the median age was 46 years (interquartile range [IQR] 38–55), and the median time taking ART was 5.7 years (IQR 3.5–8.9). No change was observed for weight or overall PHQ‐9 or SF‐12 outcomes. However, three mHSI items decreased at follow‐up: ‘feeling sad/down/depressed’ (bothered 6.0% vs. 3.3% of participants at least ‘a little’ before vs. after transition; adjusted p = 0.048); ‘feeling nervous/anxious’ (7.4% vs. 3.4%; adjusted p = 0.0009); and ‘nightmares, strange/vivid dreams’ (6.3% vs. 3.5%; adjusted p = 0.027). Individual PHQ‐9 or SF‐12 items also improved. Being symptom free across all measures increased from 5.1% to 11.4% ( p < 0.0001).
Conclusions
We observed no negative impacts and potential moderate improvements with DTG, providing further support for the rollout of DTG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Swiss Tropical and Public Health Institute, Basel, Switzerland.
- Molecular Virology Group, Department of Biomedicine, Basel, Switzerland.
- University of Basel, Basel, Switzerland.
- SolidarMed, Partnerships for Health, Maseru, Lesotho.
- University Hospital Basel, Basel, Switzerland.
- University of Maryland, College Park, Maryland, USA.
ORCID-Profile: Jennifer A Brown, Josephine Muhairwe, Tracy R Glass, Alain Amstutz, Nadine Tschumi, Jennifer M Belus, Thomas Klimkait, Niklaus D Labhardt
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Fondation Botnar
Zitieren
APA
Brown, J. A., Nsakala, B. L., Mokhele, K., Rakuoane, I., Muhairwe, J., Glass, T. R., Amstutz, A., Tschumi, N., Belus, J. M., Klimkait, T., & Labhardt, N. D. (2023). Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho. HIV Medicine, 24(2), 153-162. https://doi.org/10.1111/hiv.13352
Vancouver
Brown JA, Nsakala BL, Mokhele K, Rakuoane I, Muhairwe J, Glass TR, et al. Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho. HIV Medicine. 2023;24(2):153-162. doi:10.1111/hiv.13352
BibTeX
@article{Brown2023,
author = {Brown, Jennifer A and Nsakala, Bienvenu L and Mokhele, Kuena and Rakuoane, Itumeleng and Muhairwe, Josephine and Glass, Tracy R and Amstutz, Alain and Tschumi, Nadine and Belus, Jennifer M and Klimkait, Thomas and Labhardt, Niklaus D},
title = {Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho},
journal = {HIV Medicine},
year = {2023},
volume = {24},
number = {2},
pages = {153--162},
doi = {10.1111/hiv.13352}
}
EUVIMED